0A8M Stock Chart & Stats
$2.20
$0.00(0.00%)
At close: 4:00 PM EDT
$2.20
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.20 - $2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$25.10M
Enterprise Value$33.34
Total Cash (Recent Filing)$26.31M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 16, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding10,866,708
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.75
Price to Sales (P/S)0.46
P/FCF Ratio8.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside218.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$70.63M
Bulls Say, Bears Say
Bulls Say
EXXUA Launch MomentumEXXUA is showing increasingly broad commercial adoption, with revenue, prescriptions, shipments, refills and prescriber reach all expanding. Continued conversion from titration packs to full prescriptions could create a durable growth engine as the product scales beyond its early launch phase.
Attractive EXXUA Unit EconomicsFavorable product-level economics provide a foundation for operating leverage as EXXUA revenue grows. Expected mid- to high-60% gross margins can help absorb commercial investment over time, allowing incremental sales to contribute more meaningfully toward profitability and cash generation.
Improved Balance SheetLower leverage and a positive equity base improve Aytu's financial flexibility while it invests in EXXUA commercialization. The stronger balance-sheet position provides more capacity to manage ongoing losses, fund targeted growth initiatives, and withstand variability in product revenue.
Bears Say
Legacy Revenue ContractionThe decline in established product revenue creates a material transition burden for Aytu, requiring EXXUA to grow quickly enough to replace lost sales. Continued portfolio erosion can depress overall revenue, reduce operating scale, and delay the benefits of the new product's expansion.
Persistent Operating LossesAytu has not yet converted its commercial platform into consistent profitability, and launch spending is currently exceeding the contribution from revenue growth. Persistent losses constrain internally funded investment and make the path to sustainable earnings dependent on successful EXXUA scaling.
Gross-to-net UncertaintyUnsettled gross-to-net patterns make reported revenue and realized pricing less predictable during the EXXUA launch. Patient assistance, guaranteed coverage and channel stocking may support adoption but can also reduce near-term visibility into demand quality, margins and cash conversion.
Aytu BioScience News
0A8M FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest share price was $2.20 and its highest was $2.20 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Aytu BioScience Inc’s market cap is $25.10M.
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is Nov 16, 2026 which is in 51 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Sep 22, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.29.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -0.34.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 10,866,708 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in GB:0A8M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aytu BioScience Inc
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
0A8M Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: EXXUA's initial commercial launch shows strong early traction with accelerating prescription and shipment trends, encouraging payer coverage and attractive unit economics, and the RxConnect program appears to be reducing access friction. Offsetting this are significant year-over-year declines in legacy revenue, a quarter with a net loss and negative adjusted EBITDA, an inventory write-down, and near-term gross-to-net and cash-use volatility while the launch investment continues. Given the early-stage but tangible commercial progress balanced against meaningful near-term financial headwinds, the tone is cautiously optimistic but still transitional.View all GB:0A8M earnings summaries0A8M Stock 12 Month Forecast
Average Price Target
$7.00
▲(218.18% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
TherapeuticsMD
―
RedHill Biopharma
―
Cumberland Pharmaceuticals
―
Eton Pharmaceuticals
―